Antisense oligonucleotides of human regulatory subunit RI- of camp dependent protein kinases for the treatment of cancer
Patent 5627158 Issued on May 6, 1997. Estimated Expiration Date: May 6, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP-dependent protein kinases are disclosed along with pharmaceutical compositions containing these oligonucleotides as the active ingredients. These antisense oligonucleotides are useful for inhibiting the growth of cancer.
Other References
Tortora, G. and Cho-Chung, Y.S., Type II Regulatory Subunit of Protein Kinase Restores cAMP-dependent Transcription in a cAMP-unresponsive Cell Line, J. Biol. Chem. 265(30):18067-18070 (Oct. 25, 1990)
Tortora, G. et al., Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells, Proc. Natl. Acad. Sci. USA 86:2849-2852 (Apr. 1989)
Tortora, G. et al., A RI subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase inhibits proliferation of human HL-60 promyelocytic leukemia, Proc. Am. Assoc. Canc. Res. Annu. Meet. 31:38 (1990), Abstract No. 220
Tortora, G. et al., Site-Selective cAMP Analogs at Micromolar Concentrations Induce Growth Arrest and Differentiation of Acute Promyelocytic, Chronic Myelocytic, and Acute Lymphocytic Human Leukemia Cell Lines, Blood 71(1):230-233 (Jan. 1988)
Taylor, S.S., et al., cAMP-dependent protein kinase: prototype for a family of enzymes, FASEB J. 2:2677-2685 (1988)
Tortora, G. et al., An antisense oligodeoxynucleotide targeted against the type IIଲ regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects, Proc. Natl. Acad. Sci. USA 87:705-708 (Jan. 1990)
Tortora, G., et al., Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase, Proc. Natl. Acad. Sci. USA 88:2011-2015 (Mar. 1991)
Stein, C.A. and Cohen, J.S., Phosphorothioate Oligodeoxynucleotide Analogues, in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, Cohen, ed., pp. 97-117, Boca Raton, Florida, CRC Press, Inc. (1989)
Sugden, P.H., and Corbin, J.D., Adenosine 3':5'-Cyclic Monophosphate-Binding Proteins in Bovine and Rat Tissues, Biochem. J. 159:423-437 (1976)
Tagliaferri, P. et al., Reverse Transformation of Harvey Murine Sarcoma Virus-transformed NIH/3T3 Cells by Site-selective Cyclic AMP Analogs, J. Biol. Chem. 263(1):409-416 (Jan. 5, 1988)
Schwartz, D.A. and Rubin, C.S., Identification and Differential Expression of Two Forms of Regulatory Subunits (RII) of cAMP-dependent Protein Kinases II in Friend Erythroleukemic Cells, J. Biol. Chem. 260(10):6296-6303 (May 25, 1985)
Scott, J.D. et al., The molecular cloning of a type II regulatory subunit of the cAMP-dependent protein kinase from rat skeletal muscle and mouse brain, Proc. Natl. Acad. Sci. USA 84:5192-5196 (Aug. 1987)
Stein, C.A. and Cohen, J.S., Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review, Canc. Res. 48:2659-2668 (May 15, 1988)
Potera, C., `Reverse Transformation` Studies Provide Clues for Treating Malignancies, Genetic Engineering News 5(8):20 (Sep. 1985)
Robinson-Steiner, A.M. and Corbin, J.D., Probable Involvement of Both Intrachain cAMP Binding Sites in Activation of Protein Kinase, J. Biol. Chem. 258(2):1032-1040 (Jan. 25, 1983)
Sandberg, M. et al., Molecular Cloning, cDNA Structure and Deduced Amino Acid Sequence for a Type I Regulatory Subunit of cAMP-Dependent Protein Kinase from Human Testis, Biochem. Biophys. Res. Comm. 149(3):939-945 (Dec. 31, 1987)
Øgreid, D. et al., Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination: Principles for optimizing the isozyme specificity of analog combinations, Eur. J. Biochem. 150:219-227 (1985)
Øyen, O. et al., Human testis cDNA for the regulatory subunit RII of cAMP-dependent protein kinase encodes an alternate amino-terminal region, FEBS Letts. 246(1,2):57-64 (Mar. 1989)
Paterson, B.M. et al., Structural gene identification and mapping by DNA.cndot.mRNA hybrid-arrested cell-free translation, Proc. Natl. Acad. Sci. USA 74(10):4370-4374 (Oct. 1977)
Lee, D.C. et al., Isolation of a cDNA clone for the type I regulatory subunit of bovine cAMP-dependent protein kinase, Proc. Natl. Acad. Sci. USA 80:3608-3612 (Jun. 1983)
Levy, F.O., et al., Molecular Cloning, Complementary Deoxyribonucleic Acid Structure and Predicted Full-Length Amino Acid Sequence of the Hormone-Inducible Regulatory Subunit of 3'-5'-Cyclic . . . , Mol. Endo. 2(12):1364-1373 (1988)
Mizuno, T. et al., A unique mechanism regulating gene expression: Translational inhibition by a complementary RNA transcript (micRNA), Proc. Natl. Acad. Sci. USA 81:1966-1970 (Apr. 1984)
Iyer, R.P. et al., 3H-1,2-Benzodithiole-3-one 1,1-Dioxide as an Improved Sulfurizing Reagent in the Solid-Phase Synthesis of Oligodeoxyribonucleoside Phosphorothioates, J. Am. Chem. Soc. 112:1253-1254 (1990)
Jahnsen, T., et al., Molecular Cloning, cDNA Structure, and Regulation of the Regulatory Subunit of Type II cAMP-dependent Protein Kinase from Rat Ovarian Granulosa Cells, J. Biol. Chem. 261(26):12352-12361 (Sep. 15, 1986)
Katsaros, D. et al., Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth, FEBS Letts. 233(1):97-103 (Oct. 1987)
Corbin, J.D. et al., The Distribution and Dissociation of Cyclic Adenosine 3':5'-Monophosphate-dependent Protein Kinases in Adipose, Cardiac, and Other Tissues, J. Biol. Chem. 250(1):218-225 (Jan. 10, 1975)
Heywood, S.M., tcRNA as a naturally occurring antisense RNA in eukaryotes, Nucl. Acids Res. 14(16):6771-6772 (1986)
Hofmann, F. et al., Concentrations of Cyclic AMP-dependent Protein Kinase Subunits in Various Tissues, J. Biol. Chem. 252(4):1441-1447 (Feb. 25, 1977)
Clegg, C.H. et al., Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase, Proc. Natl. Acad. Sci. USA 85:3703-3707 (Jun. 1988)
Cohen, J.S., Topics in Molecular and Structural Biology, Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, Natl. Cancer Inst., Bethesda, Md. pp. 1-6, Boca Roton, Florida, CRC Press, Inc. (1989)
Cho-Chung, Y., et al., An antisense oligodeoxynucleotide targeted against the type I regulatory subunit (RI) mRNA of cAMP-dependent protein kinase (PKA) inhibits the growth of LS-174T human colon carcinoma in athymic mice, Proc. Am. Assoc. Canc. Res. Annu. Meet. 32:277 (1991), Abstract No. 1645
Cho-Chung, Y.S. et al., A RI subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase blocks proliferation in human and rodent cancer cell lines by-passing exogenous cAMP effect, Proc. Am. Assoc. Canc. Res. Annu. Meet. 31:29 (1990) Abstract No. 171
Cho-Chung, Y.S. et al., Site-Selective Cyclic AMP analogs as New Biological Tools in Growth Control, Differentiation, and Proto-oncogene Regulation, Canc. Invest. 7(2):161-177 (1989)
Ally, S., Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3'5',-cyclic monophosphate provides a biological means for control of human colon cancer cell growth, Proc. Natl. Acad. Sci. USA 85:6319-6322 (Sep. 1988)
Campbell, J.M. et al., Oligodeoxynucleoside Phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid, J. Biochem. Biophys. Meth. 20:259-267 (1990)
Cho-Chung, Y.S., Site-Selective 8-Chloro-Cyclic Adenosine 3',5'-Monophosphate as a Biologic Modulator of Cancer: Restoration of Normal Control Mechanisms, J. Natl. Canc. Inst. 81(13):982-987 (Jul. 5, 1989)
C. Stein et al., Science, vol. 261 (20 Aug. '93) pp. 1004-1012
B. Tseng et al., Cancer Gene Therapy, vol. 1, No. 1 (Mar. 94) pp. 65-71
R. Weiss, Science News, vol. 139 (16 Feb. '91) pp. 108-109
R. Phillips et al., J.N.C.I., vol. 82, No. 18(19 Sep. '90) pp. 1457-1468
K. Smith, et al. Eur. J. Cancer Clin. Oncol., vol. 21, no. 2 ('85) pp. 249-256
K. Zirri, et al., Cancer Letters, vol. 72 ('93) pp. 39-44
J. Milligan et al., J. Med. Chem., vol. 36 No. 14 (9 Jul. '93) pp. 1923-1937 (Ex. 9)
E. Uhlmann et al. Chemical Reviews, vol. 90, #4 (1990) pp. 543-584
C. Mirabelli et al. Anti-Cancer Drug Design, vol. 6 (1991) pp. 647-661
P. Westermann et al. Biomed, Biochem. Acta, vol. 48 (1989) pp. 85-93
J. Potts P.N.A.S., vol. 88 (1991) pp. 1516-1520
A. Storey Nucl. Acids Res., vol. 19, #15 (1991) pp. 4109-4114
L. Perlaky et al. Anti-Cancer Drug Design, vol. 7 (1992) pre-print
M. Ratajczak et al. P.N.A.S., vol. 89 (1992) pp. 11823-11827
D. Becker et al. The EMBO Journal, vol. 8, #12 ('89) pp. 3685-3691
Y. Furukawa Science, vol. 250 (1990) pp. 805-808
C. Szczylik et al. Science, vol. 253 ('91) pp. 562-565
D. Jaskulski et al. Science, vol. 240 ('88) pp, 1544-1546
S. Crooke Annu. Rev. Pharmacol. Toxicol. ('92 ) vol. 32, pp. 329-37
May 6, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
